Netherlands: Covid-19: Emergency Act temporarily amends Dutch Patents Act

Isabel Rutten

In June 2020, the Dutch House of Representatives passed an Emergency Act to temporarily amend the Dutch Patent Act, allowing patent holders and applicants more time to secure and preserve their patents. Before the introduction of the Emergency Act, the Covid-19 pandemic may have affected companies that owned patents or were in the process of Read More

Terumo loses appeal against Dutch TV broadcaster

Lars Braams

Two anonymous whistleblowers informed the media about certain serious flaws with respect to Terumo’s syringes, stents and catheters. In the first broadcast of the Dutch TV show “EenVandaag” by AVROTROS it is stated that the syringes can contain (liquid) glue that might contaminate the medicine and the patient. In the second broadcast the quality control Read More

MA for melatonin refused, Dutch court agrees

Lars Braams

A Marketing Authorization (MA) is required for selling melatonin in dosages above 0.3 mg. The Dutch Health Care Inspectorate (IGZ) warned repeatedly that it will enforce against the sale of such products, without having an MA. On 16 June, the administrative court of Amsterdam published a decision according to which the decision of the Dutch Read More

Covid-19 coronavirus: Measures introduced to mitigate healthcare consequences in the Netherlands

Iradj Nazaryar

In March and April 2020, the Dutch Health and Youth Care Inspectorate (IGJ) announced various measures to mitigate the consequences of the Covid-19 coronavirus pandemic on the Dutch healthcare sector: Permission to supply medical devices that are not CE marked . Manufacturers and suppliers may temporarily supply medical devices without CE markings provided there are Read More

Netherlands – Reduction of reimbursement of medicines

Sophie van Asten

The Dutch Minister of Care announced in his letter of 27 January 2020 to the House of Representatives that the Dutch medicine reimbursement system will be modernised. The current reimbursement limits are still based on the market situation in 1998. According to the minister, nowadays there would be cheaper alternatives for many reimbursed medicines. Therefore, Read More